Navigation Links
Accumetrics Signs Development & Supply Agreement With Portola Pharmaceuticals, Inc.
Date:3/2/2011

SAN DIEGO, March 2, 2011 /PRNewswire/ -- Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow System, the first rapid and easy-to-use point-of-care diagnostic system for measuring platelet reactivity to multiple antiplatelet agents, announced today that the company has signed an agreement with Portola Pharmaceuticals, Inc. to develop and supply the VerifyNow System and VerifyNowTests for use in clinical trials.

The VerifyNow System is widely used by practicing physicians to assess patients' platelet response to various antiplatelet therapies already available on the market, such as aspirin, P2Y12 inhibitors (e.g. Plavix® and Effient®)and GP IIb/IIIa inhibitors. The VerifyNow System is also a frequently used tool of clinical researchers to measure the antiplatelet effect of drugs in development.  By incorporating the VerifyNow System in pharmaceutical clinical trials, data are generated to support the integration of platelet reactivity testing in the patient care pathway as new agents are introduced to the market.

"With the signing of this agreement, Accumetrics is solidifying its role as a premier partner of pharmaceutical companies in the development and validation of new and emerging antiplatelet drugs," said Timothy I. Still, President and CEO of Accumetrics.  "With the trend towards individualized and targeted approaches to treating patients, the VerifyNow System plays an important role at both the commercial and development ends of the spectrum."

The VerifyNow System is widely used in various clinical settings where antiplatelet medications are prescribed to reduce the occurrence of future thrombotic events such as heart attack and stroke.

About Accumetrics Accumetrics is committed to advancing medical understanding of platelet function and enhancing quality of care for patients receiving antiplatelet therapies by providing industry-leading and widely accessible diagnostic tests for rapid platelet function assessment.

Accumetrics' VerifyNow System is the first rapid and easy-to-use platform to help physicians determine an individual's response to multiple antiplatelet agents. Addressing every major antiplatelet drug, including FDA-cleared products for aspirin, P2Y12 inhibitors (e.g. prasugrel (Effient) and clopidogrel (Plavix)), and GP IIb/IIIa inhibitors (e.g. ReoPro® and Integrilin®), the VerifyNow System provides a valuable tool to help physicians make informed treatment decisions. For more information about the Company and its products, visit www.accumetrics.com.

The Accumetrics logo and VerifyNow are registered trademarks of Accumetrics, Inc. ReoPro is a registered trademark of Centocor, Inc. Integrilin is a registered trademark of Millennium Pharmaceuticals. Plavix is a registered trademark of sanofi-aventis. Effient is a registered trademark of Eli Lilly and Company. CONTACT: Megan RusnackLippert/Heilshorn & Associates212-838-3777mrusnack@lhai.comTimothy I. StillPresident and CEOAccumetrics858-404-8260press@accumetrics.com
'/>"/>

SOURCE Accumetrics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Accumetrics Closes 2010 With Positive Outlook
2. Accumetrics, Inc., Daiichi Sankyo, Inc. and Eli Lilly and Company Launch Strategic U.S. Collaboration
3. Accumetrics Closes 2009 with Positive Outlook
4. Accumetrics to Present at the 21st Annual Piper Jaffray Health Care Conference
5. Accumetrics Announces $16.5M in New Capital Financing
6. Accumetrics, Inc. Announces GRAVITAS Trial 50 Percent Enrolled
7. Accumetrics Announces the Launch and First Patient Enrolled Into the GRAVITAS Trial
8. Accumetrics Announces $28.8 Million Financing and Initiation of Pivotal Clinical Trial
9. Source Precision Medicine, Inc., dba SourceMDx Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A. of the firm of Finn, Warnke & Gayton, LLP
10. Breast Imaging Company, TechniScan, Signs Manufacturing Agreement With Texas Company
11. Royal Fornia Electronic Device Co., Ltd. Signs Technology Licensing Agreement to Integrate Masimo rainbow SET Pulse CO-Oximetry Into New Patient Monitors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2017)... 6, 2017   Provista, a proven leader ... billion in purchasing power, today announced a new resource ... The Newsroom is the online home for case ... expert bios, news releases, slideshows and events. ... wealth of resources at their fingertips, viewers can also ...
(Date:10/4/2017)... 2017 OBP Medical , a ... devices, today announced regulatory approval from ... Agência Nacional de Vigilância Sanitária (ANVISA)) to market ... retractor with integrated LED light source and smoke ... exposure of a tissue pocket or cavity during ...
(Date:10/2/2017)... Halo Labs announces the European launch of their new ... at MIBio 2017 in Cambridge, U.K on ... in biopharmaceutical samples with unprecedented speed and sensitivity while using far ... Membrane Imaging. ... particle analysis system ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... the most popular and least understood books in the Holy Scriptures, Revelation. The Book ... have baffled scholars for centuries. Many have tossed it off as mere rubbish, but ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the loss ... author, William Nowers. Captain Nowers and his wife, Millie, have six children, ten ... the Navy. Following his career as a naval aviator and carrier pilot, he ...
(Date:10/12/2017)... ... 2017 , ... The company has developed a suite of ... authorities worldwide. From Children’s to Adults 50+, every formula has been developed by ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, Preservative ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the ... – Miles by Moonlight to raise money for the American Heart Association Heart Walk. ... , Teams will work together to keep their treadmills moving for 5 hours. Treadmills ...
Breaking Medicine News(10 mins):